State law tracker

HB 2871 · 2025

Appropriation; ibogaine; clinical research study

House-engrossed text would appropriate $5 million, with matching funds, for ibogaine research on neurological conditions including PTSD and traumatic brain injury.

Reviewed 2026-10-31

SB 58 · 2023

Decriminalize certain natural psychedelics

Reviewed 2026-10-11

AB 1103 · 2025

Controlled substances: research

Signed October 10, 2025. Changes how the Research Advisory Panel reviews Schedule I and II research, with temporary expedited review through January 1, 2028.

Reviewed 2026-10-31

Proposition 122 / SB23-290 · 2023

Natural Medicine Health Act and implementing law

Reviewed 2026-10-11

SB 2184 · 2025

Compassionate Use and Research of Entheogens Act

Senate version of a regulated psilocybin services program with licensing and an advisory board. Introduced February 7, 2025.

Reviewed 2026-10-31

HB 1143 · 2025

Compassionate Use and Research of Entheogens Act

Would create a psilocybin advisory board and licensed psilocybin services. Referred to the House Rules Committee on January 9, 2025.

Reviewed 2026-10-31

SB 43 · 2026

Provides relative to psychedelic-assisted therapy

Became Act 956. Creates a Psychedelic-Assisted Therapy Initiative and supports clinical studies involving ibogaine, MDMA and psilocybin.

Reviewed 2026-10-31

LD 1034 · 2025

An Act to Decriminalize Personal Possession of Therapeutic Amounts of Psilocybin for Adults

Failed final enactment in the House (72–74) on June 9, 2025, and in the Senate (16–16) on June 10, 2025.

Reviewed 2026-10-31

SB 1009 / HB 548 · 2024

Task Force on Responsible Use of Natural Psychedelic Substances

Reviewed 2026-10-11

Question 4 · 2024

Natural psychedelic substances ballot measure

Reviewed 2026-10-11

HB 6020 · 2026

Participation in ibogaine clinical trials

Would create grants for FDA-overseen ibogaine clinical trials. Introduced May 21, 2026.

Reviewed 2026-10-31

HB 4686 · 2025

Allow psilocybin or psilocin under certain circumstances

Would protect limited personal psilocybin use by adults with documented PTSD. Introduced June 25, 2025.

Reviewed 2026-10-31

HF 100 · 2023

Psychedelic Medicine Task Force

Reviewed 2026-10-11

S 2283 · 2025

Pilot program for psilocybin research; makes an appropriation

Enacted as P.L. 2025, c.296. Creates a hospital-based psilocybin research pilot that follows FDA and DEA rules. It does not legalize adult use.

Reviewed 2026-10-31

SB 219 · 2025

Medical Psilocybin Act

Reviewed 2026-10-11

A628 · 2025

Natural hallucinogen adult-use proposal

Would change state law on adult possession and use of specified natural hallucinogens. It is not enacted and does not currently create legal access.

What happens next: Referred to Assembly Health; awaiting committee consideration. No confirmed upcoming hearing date recorded.

Last action: 2026-01-07 · Reviewed 2026-10-30

A2142A / S5303A · 2025

Allows growth, cultivation and adult use of psilocybin for certain health conditions

Would create state protections for certain psilocybin uses for specified health conditions. This remains a proposal; it does not currently authorise treatment or retail access.

What happens next: Awaiting committee consideration. No confirmed upcoming hearing date recorded.

Last action: 2026-05-08 · Reviewed 2026-10-31

Measure 109 · 2020

Oregon Psilocybin Services Act

Reviewed 2026-10-11

HB1439 · 2025

FDA-linked psilocybin access proposal

Would link a state psilocybin access or scheduling pathway to federal regulatory action. This is a proposal, not an operating supervised-use program.

What happens next: Referred to House Health; awaiting committee consideration. No confirmed upcoming hearing date recorded.

Last action: 2025-05-12 · Reviewed 2026-10-30

SB1149 · 2026

Pharmaceutical synthetic psilocybin scheduling proposal

Would align state scheduling of pharmaceutical synthetic psilocybin with federal law after specified federal actions. It does not legalise general mushroom possession or retreats.

What happens next: Referred to Senate Judiciary; awaiting committee consideration. No confirmed upcoming hearing date recorded.

Last action: 2026-01-23 · Reviewed 2026-10-30

HB 1802 · 2021

Psilocybin treatment research study for veterans

Reviewed 2026-10-11

SB 2308 · 2025

Establishment of a consortium to conduct a clinical trial of ibogaine treatment

Reviewed 2026-10-12

HB 167 · 2024

Mental illness psychotherapy drug pilot

Reviewed 2026-10-11

S.114 · 2024

An act relating to the establishment of the Psychedelic Therapy Advisory Working Group

Act 126, signed May 29, 2024 and effective July 1, 2024, established a working group to review evidence and recommend whether Vermont should create a psychedelic therapy program. It did not legalize psychedelic treatment or establish a treatment-access program.

What happens next: The working group was directed to report its findings and recommendations; any treatment-access program would require separate legislative action.

Last action: 2024-05-29 · Reviewed 2026-10-31

HB 1433 · 2025

Concerning access to psychedelic substances

Heard in House Health Care & Wellness in February 2025; reintroduced and retained in present status January 12, 2026.

Reviewed 2026-10-31

SB 5263 · 2023

Psilocybin task force and pilot

Reviewed 2026-10-11

SB 5201 · 2025

Concerning access to psychedelic substances

Senate companion to HB 1433; reported from Health & Long-Term Care in February 2025.

Reviewed 2026-10-31